South Korean Team Builds Genetic Tool to Decode Lupus Risk and Guide Precision Medicine Research

A Korean Genetic Map Targets a Difficult Part of Lupus Research

South Korean scientists have developed a genetic analysis tool using genomic data from nearly 70,000 Koreans to examine one of the most complex regions of human DNA linked to lupus. The tool gives researchers a more detailed way to investigate immune genes whose variations can influence the risk of developing the disease.

The research was led by Professor Bae Sang-cheol of Hanyang University Hospital for Rheumatic Diseases, working with Professor Kim Kwangwoo at Kyung Hee University and the National Institute of Health's genome research department. Their collaboration brings together clinical knowledge, genetic analysis and national research infrastructure.

The tool, called an MHC imputation reference panel, incorporates data from both lupus patients and healthy controls. Comparing these groups helps researchers identify genetic differences associated with disease. The panel is described as the first of its kind to incorporate Korean genomic data on this scale, improving the precision of research involving East Asian populations.

Lupus, formally known as systemic lupus erythematosus (SLE), is a chronic autoimmune disorder. A person's immune system mistakenly attacks healthy tissues and organs, potentially affecting the skin, joints, kidneys, brain and other parts of the body. The result can be a wide range of symptoms and complications.

The Korean team's work addresses a longstanding difficulty: some of the immune genes most relevant to lupus sit in a densely packed region that has been exceptionally hard to analyze. By making that region easier to study, the researchers aim to help explain why lupus develops and support the search for treatments tailored to a patient's genetic profile.

Why Chromosome 6 Matters

The major histocompatibility complex (MHC) is a region on chromosome 6 containing hundreds of genes involved in regulating the immune system. Among them are the human leukocyte antigen (HLA) family and the complement component 4 (C4) gene. Both have long been suspected of contributing to autoimmune conditions, including lupus, rheumatoid arthritis and inflammatory bowel disease.

The concentration and complexity of immune genes in this region make it difficult to work out which variations matter most. Researchers need enough detail to separate the contributions of different genes, rather than treating the region as a single broad signal of disease risk.

Bae, the professor leading the research at Hanyang University Hospital for Rheumatic Diseases, described the challenge and the intended reach of the new tool:

The immune-related genes located in the MHC region on chromosome 6 are extremely complex, making them difficult to analyze. With this new tool, we can now accurately and easily analyze this region. This creates a foundational infrastructure that could be used to uncover genetic causes of not only lupus, but also other autoimmune diseases.

An imputation reference panel gives researchers a genetic reference against which they can analyze other genomic data. Here, the purpose is to examine the MHC region at greater resolution, helping scientists identify variations that broader genetic studies have struggled to separate.

What HLA and C4 Reveal About Risk

The researchers found that specific amino acid changes in HLA genes and variations in the number of C4 genes each independently influence the risk of developing lupus. That finding gives scientists two distinct genetic contributions to investigate within the same crowded region.

Amino acids are the building blocks of proteins. Certain changes in HLA can alter how the immune system recognizes antigens, the targets it examines when deciding what to respond to. Such changes can contribute to healthy tissue being misidentified as something foreign.

C4 has a different role. It belongs to the complement system, part of the body's immune defenses and an important contributor to immune balance. A lower number of C4 genes can reduce the production of complement proteins, making that balance more vulnerable to disruption and autoimmunity.

The ability to study HLA changes and C4 gene numbers separately matters because lupus involves several biological processes at once. A more detailed genetic picture can help researchers connect a particular risk signal with the immune mechanism behind it.

Why Korean Reference Data Make a Difference

Most genetic reference panels used in research have been built from populations in the United States and Europe. Their accuracy for East Asian populations has been limited when important genetic variations found in Koreans and other Asian populations were missing from the reference data.

The new panel addresses that gap through its use of genomic information from nearly 70,000 Koreans. Including people with lupus and healthy controls gives researchers a population reference suited to investigating differences associated with the disease.

Lupus genetics includes both shared and population specific patterns. STAT4 and BLK are examples of risk genes shared across populations of European and Asian ancestry. ETS1, IKZF1 and SLC15A4 appear to be more specific to Asian populations.

Those differences help explain why researchers need genetic tools developed for the populations they are studying. A reference that represents relevant variations more fully can improve the identification of risk factors and support research toward more accurate diagnosis and treatment.

The issue reaches beyond a single Korean study. Biomedical research has historically concentrated on people of European descent, leaving gaps in knowledge about genetic risks in Asian populations. Those gaps have contributed to disparities in diagnosis, treatment and health outcomes for millions of people across Asia.

Lupus Has More Than One Genetic Cause

More than 200 genetic factors contribute to lupus, each adding a small amount to a person's risk. Infections, hormonal changes and lifestyle factors also influence whether the disease develops. That combination makes lupus much harder to explain than a disorder caused by a single mutation.

Genome wide association studies (GWAS), which search across the genome for variations associated with disease, and transcriptome wide association studies (TWAS), which examine associations involving gene activity, have identified more than 100 lupus risk loci. A locus is a location in the genome associated with a trait or condition.

The two figures describe different aspects of the research: more than 200 genetic factors contribute to risk, while more than 100 genomic locations have been identified through these studies. Even after a location is identified, scientists may still need to determine which gene and biological mechanism are responsible.

The Korean reference panel provides a way to examine the MHC region in greater detail and clarify which variants are driving disease risk. Its value lies in connecting broad genetic associations with more specific changes that researchers can investigate.

Lupus also varies widely between individuals and populations. Genetic risk factors differ, and so do the symptoms and organs affected. Understanding those differences is central to developing treatments suited to individual patients.

How Genetics Could Help Match Patients With Treatments

Precision medicine means using information about an individual, including their genetic profile, to guide treatment. For lupus, the goal is to understand which combinations of genetic and environmental factors are relevant to a particular patient, then use that knowledge to choose a more suitable therapy.

Bae explained how identifying a particular genetic contribution could guide future treatment choices:

By understanding these complex combinations, we can move toward personalized treatment. For example, if we identify that a patient's disease is linked to the C4 gene—one of the strongest known genetic risk factors—we can choose a drug that specifically targets that mechanism. This opens the door not just to more effective therapies but also to developing new drugs.

The proposed benefits include earlier diagnosis, more accurate risk assessment and the selection of therapies most likely to work for each patient. Understanding the mechanisms involved could also give drug developers more specific targets.

The immediate achievement is a research tool. Further work is needed to turn its genetic findings into effective therapies and to establish how they can guide care. The same approach holds promise for other autoimmune and inflammatory conditions because the MHC region is involved in a wide range of diseases.

Bae has described autoimmune diseases as even more complex than cancer because genetic combinations vary so much from person to person. Sorting patients by their genetic profiles and matching them with suitable drugs is the treatment strategy the research seeks to support.

A Wider Effort to Map Immune Diversity in Asia

The Asian Immune Diversity Atlas (AIDA) is another initiative addressing gaps in population representation by mapping immune cell diversity across Asian populations. The Korean MHC reference panel complements that effort with a detailed genetic resource for studying a particularly complex immune region.

Shyam Prabhakar, associate director at the Genome Institute of Singapore, explained why population specific reference resources matter for clinical research:

Human biological diversity—influenced by factors such as age, sex and genetic ancestry—significantly impacts health outcomes, making population-specific reference atlases essential for accurate clinical insights.

The Korean panel is being made publicly available through Korea's national CODA system, a genomic infrastructure intended to support open access research. Scientists can use the resource for studies of lupus, other autoimmune disorders, infectious diseases and chronic inflammatory illnesses.

Access to a detailed reference panel could support research into disease prediction and biomarkers, measurable biological features that help scientists investigate disease. Its availability also allows researchers outside Korea to build on the work and study immune genetics in East Asian populations.

The shared purpose of these initiatives is practical: better representation in research should give scientists a more accurate starting point when investigating health and disease in the people those studies are intended to help.

The Disease Burden Extends Beyond Genetics

Lupus affects an estimated 3.4 million people worldwide, with 400,000 new cases diagnosed each year. It is most common among women between puberty and menopause, and its incidence is rising globally.

Genetic susceptibility is only part of the explanation. Infections, including COVID-19, ultraviolet light exposure and hormonal influences can play a role in triggering disease onset. Studying these exposures alongside genetics is necessary to understand why people with different risk profiles become ill.

Studies from South Korea and Japan have found an increased risk of autoimmune diseases, including lupus, during the year following COVID-19 infection. Vaccination against COVID-19 has been found to reduce that risk, linking infection prevention with the wider effort to limit autoimmune disease burden.

Some research has also indicated a modestly increased risk of lupus following vaccination with mRNA vaccines against COVID-19. Continued monitoring and research are needed to understand that finding alongside the protection vaccination provides against the autoimmune risks associated with infection.

Inside the body, lupus involves a breakdown in the ability to distinguish healthy tissue from foreign targets. Both the innate immune system, the body's immediate defenses, and the adaptive immune system, which develops more specific responses, are involved.

The disease process includes excessive production of autoantibodies, antibodies directed against the body's own tissues, and disrupted cytokine signaling. Cytokines are chemical messages used by immune cells. Changes in these processes can sustain inflammation and damage tissue.

The complement system, particularly C4, is central to maintaining immune balance, and its dysfunction is a key feature of lupus. That biological role helps explain why measuring genetic variation in C4 is an important part of the Korean team's work.

The Infrastructure Behind the Research

South Korea's biomedical infrastructure helped make the project possible. Large biobanks, integrated health databases and collaborative research networks provide the samples, information and partnerships needed for genetic studies involving many thousands of people.

Resources supporting this wider research environment include the KOrea Renal biobank NEtwoRk System TOward Next-generation analysis (KORNERSTONE) and the Korean Variant Archive (KOVA). Such initiatives provide material and genetic information for studies and support the development of new diagnostic and therapeutic approaches.

Making the MHC panel publicly available extends the value of that infrastructure. Researchers around the world can use it to investigate autoimmune and inflammatory diseases, compare findings and pursue further discoveries that may eventually improve care.

The work also places Korea's research capacity within a broader effort to improve immunogenetics, the study of genetic influences on the immune system, and precision medicine. Its potential benefits extend beyond Korea because the resource addresses a gap affecting research across East Asia.

What Researchers Still Need to Do

Larger and more diverse groups of participants are needed to validate the findings. Researchers also need to examine the functional consequences of the identified variants, meaning how those genetic changes alter the way cells and immune processes work.

Studies combining genetic information with environmental exposures, lifestyle factors and immune profiling will be needed to explain disease onset and progression more fully. Immune profiling examines the features and activity of a person's immune system, adding another layer to the genetic picture.

The next stage is to connect those biological findings with treatments that help patients. The Korean panel gives researchers a more precise way to investigate a difficult region of the genome, while the work of testing therapies and applying the findings in care remains ahead.

Key Points

• South Korean researchers developed an MHC imputation reference panel using genomic data from nearly 70,000 Koreans, including lupus patients and healthy controls.
• The tool examines a complex immune region on chromosome 6 and improves the precision of genetic research involving East Asian populations.
• Specific amino acid changes in HLA genes and differences in C4 gene numbers independently influence lupus risk.
• Lupus involves more than 200 genetic factors, along with environmental influences, and affects an estimated 3.4 million people worldwide.
• The panel is being made publicly available through Korea's CODA system for research into lupus and other immune related conditions.
• Further validation and studies of biological mechanisms are needed to translate the findings into treatments tailored to individual patients.